Gainers
- Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved upwards by 115.6% to $0.17 during Thursday's regular session. The company's market cap stands at $21.4 million.
- 89bio (NASDAQ:ETNB) shares rose 85.45% to $14.98. The company's market cap stands at $1.1 billion.
- Aptevo Therapeutics (NASDAQ:APVO) stock rose 33.31% to $1.88. The market value of their outstanding shares is at $4.6 million.
- Quantum-Si (NASDAQ:QSI) stock moved upwards by 26.53% to $1.59. The company's market cap stands at $255.1 million.
- Psyence Biomedical (NASDAQ:PBM) shares rose 25.8% to $4.68.
- Intellia Therapeutics (NASDAQ:NTLA) shares moved upwards by 22.56% to $15.21. The market value of their outstanding shares is at $1.3 billion.
Losers
- Replimune Group (NASDAQ:REPL) stock declined by 44.3% to $3.18 during Thursday's regular session. The company's market cap stands at $445.6 million.
- CDT Equity (NASDAQ:CDT) shares fell 25.87% to $0.67. The company's market cap stands at $2.7 million.
- BioCardia (NASDAQ:BCDA) stock decreased by 21.83% to $1.2. The market value of their outstanding shares is at $8.9 million.
- Salarius Pharmaceuticals (NASDAQ:SLRX) shares fell 18.46% to $4.53. The company's market cap stands at $2.8 million.
- Liminatus Pharma (NASDAQ:LIMN) shares fell 18.26% to $1.3. The company's market cap stands at $43.0 million.
- Curanex Pharmaceuticals (NASDAQ:CURX) stock fell 16.84% to $1.26. The market value of their outstanding shares is at $42.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
APVOAptevo Therapeutics Inc
$1.450.69%
BCDABioCardia Inc
$1.38-1.43%
CDTCDT Equity Inc
$0.6712-2.51%
CURXCuranex Pharmaceuticals Inc
$0.7854-%
ETNB89bio Inc
$14.69-0.07%
LIMNLiminatus Pharma Inc
$1.64-1.80%
NTLAIntellia Therapeutics Inc
$16.85-0.41%
PBMPsyence Biomedical Ltd
$3.272.51%
QSIQuantum-Si Inc
$1.38-1.08%
REPLReplimune Group Inc
$4.27-1.61%
SLRXSalarius Pharmaceuticals Inc
$4.148.95%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.